BACKGROUND: HIV pretreatment drug resistance (PDR) to NNRTIs in persons initiating ART is increasing in Mexico. OBJECTIVES: To compare HIV PDR in eight sub-regions of Mexico. PATIENTS AND METHODS: A large PDR survey was implemented in Mexico (September 2017-March 2018) across eight sub-regions. All larger clinics (which provide ART to 90% of all initiators) were included, allocating sample size using the probability-proportional-to-size method. Both antiretroviral-naive and prior antiretroviral-exposed persons were included. HIV PDR levels were estimated from pol Sanger sequences obtained at a WHO-designated laboratory. RESULTS: A total of 2006 participants were enrolled from 74 clinics. PDR to NNRTIs was higher than to other drug classes (P < 0.0001), crossing the 10% threshold in the North-East, East, South-West and South-East. NNRTI PDR was higher in the South-West (P = 0.02), coinciding with the highest proportion of restarters in this sub-region (14%). We observed higher PDR prevalence to any drug in women compared with men (16.5% versus 12.2%, P = 0.04). After multivariable adjustment, higher NNRTI PDR remained significantly associated with previous antiretroviral exposure in the Centre-North, North-West, South-West and South-East [adjusted OR (aOR): 21, 5, 8 and 25, respectively; P < 0.05]. Genetic network analyses showed high assortativity by sub-region (P < 0.0001), with evidence of drug resistance mutation transmission within local clusters. CONCLUSIONS: Diversification of the public health response to HIV drug resistance based on sub-regional characteristics could be considered in Mexico. Higher NNRTI PDR levels were associated with poorer regions, suggesting opportunities to strengthen local HIV programmes. Price and licensing negotiations of drug regimens containing integrase inhibitors are warranted.
BACKGROUND: HIV pretreatment drug resistance (PDR) to NNRTIs in persons initiating ART is increasing in Mexico. OBJECTIVES: To compare HIV PDR in eight sub-regions of Mexico. PATIENTS AND METHODS: A large PDR survey was implemented in Mexico (September 2017-March 2018) across eight sub-regions. All larger clinics (which provide ART to 90% of all initiators) were included, allocating sample size using the probability-proportional-to-size method. Both antiretroviral-naive and prior antiretroviral-exposed persons were included. HIV PDR levels were estimated from pol Sanger sequences obtained at a WHO-designated laboratory. RESULTS: A total of 2006 participants were enrolled from 74 clinics. PDR to NNRTIs was higher than to other drug classes (P < 0.0001), crossing the 10% threshold in the North-East, East, South-West and South-East. NNRTI PDR was higher in the South-West (P = 0.02), coinciding with the highest proportion of restarters in this sub-region (14%). We observed higher PDR prevalence to any drug in women compared with men (16.5% versus 12.2%, P = 0.04). After multivariable adjustment, higher NNRTI PDR remained significantly associated with previous antiretroviral exposure in the Centre-North, North-West, South-West and South-East [adjusted OR (aOR): 21, 5, 8 and 25, respectively; P < 0.05]. Genetic network analyses showed high assortativity by sub-region (P < 0.0001), with evidence of drug resistance mutation transmission within local clusters. CONCLUSIONS: Diversification of the public health response to HIV drug resistance based on sub-regional characteristics could be considered in Mexico. Higher NNRTI PDR levels were associated with poorer regions, suggesting opportunities to strengthen local HIV programmes. Price and licensing negotiations of drug regimens containing integrase inhibitors are warranted.
Authors: Kristel Van Laethem; Yoeri Schrooten; Kris Covens; Nathalie Dekeersmaeker; Paul De Munter; Eric Van Wijngaerden; Marc Van Ranst; Anne-Mieke Vandamme Journal: J Virol Methods Date: 2008-09-02 Impact factor: 2.014
Authors: Joel O Wertheim; Alexandra M Oster; Angela L Hernandez; Neeraja Saduvala; M Cheryl Bañez Ocfemia; H Irene Hall Journal: AIDS Res Hum Retroviruses Date: 2016-05-19 Impact factor: 2.205
Authors: Antoine Chaillon; Santiago Avila-Ríos; Joel O Wertheim; Ann Dennis; Claudia García-Morales; Daniela Tapia-Trejo; Carlos Mejía-Villatoro; Juan M Pascale; Guillermo Porras-Cortés; Carlos J Quant-Durán; Ivette Lorenzana; Rita I Meza; Elsa Y Palou; Marvin Manzanero; Rolando A Cedillos; Gustavo Reyes-Terán; Sanjay R Mehta Journal: Infect Genet Evol Date: 2017-06-20 Impact factor: 3.342
Authors: Santiago Ávila-Ríos; Claudia García-Morales; Margarita Matías-Florentino; Karla A Romero-Mora; Daniela Tapia-Trejo; Verónica S Quiroz-Morales; Helena Reyes-Gopar; Hezhao Ji; Paul Sandstrom; Jesús Casillas-Rodríguez; Juan Sierra-Madero; Eddie A León-Juárez; Marisol Valenzuela-Lara; Carlos Magis-Rodríguez; Patricia Uribe-Zuñiga; Gustavo Reyes-Terán Journal: Lancet HIV Date: 2016-09-14 Impact factor: 12.767
Authors: Sanjay R Mehta; Joel O Wertheim; Kimberly C Brouwer; Karla D Wagner; Antoine Chaillon; Steffanie Strathdee; Thomas L Patterson; Maria G Rangel; Mlenka Vargas; Ben Murrell; Richard Garfein; Susan J Little; Davey M Smith Journal: EBioMedicine Date: 2015-07-18 Impact factor: 8.143
Authors: Joel O Wertheim; Sergei L Kosakovsky Pond; Lisa A Forgione; Sanjay R Mehta; Ben Murrell; Sharmila Shah; Davey M Smith; Konrad Scheffler; Lucia V Torian Journal: PLoS Pathog Date: 2017-01-09 Impact factor: 6.823
Authors: Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Paul Revill; Michael R Jordan; Timothy B Hallett; Meg Doherty; Andrea De Luca; Jens D Lundgren; Mutsa Mhangara; Tsitsi Apollo; John Mellors; Brooke Nichols; Urvi Parikh; Deenan Pillay; Tobias Rinke de Wit; Kim Sigaloff; Diane Havlir; Daniel R Kuritzkes; Anton Pozniak; David van de Vijver; Marco Vitoria; Mark A Wainberg; Elliot Raizes; Silvia Bertagnolio Journal: Lancet HIV Date: 2017-11-22 Impact factor: 12.767
Authors: George K Hightower; Susanne J May; Josué Pérez-Santiago; Mary E Pacold; Gabriel A Wagner; Susan J Little; Douglas D Richman; Sanjay R Mehta; Davey M Smith; Sergei L Kosakovsky Pond Journal: PLoS One Date: 2013-06-28 Impact factor: 3.240
Authors: Nuttada Panpradist; Ingrid A Beck; Parker S Ruth; Santiago Ávila-Ríos; Claudia García-Morales; Maribel Soto-Nava; Daniela Tapia-Trejo; Margarita Matías-Florentino; Hector E Paz-Juarez; Silvia Del Arenal-Sanchez; Gustavo Reyes-Terán; Barry R Lutz; Lisa M Frenkel Journal: AIDS Date: 2020-07-15 Impact factor: 4.177
Authors: Margarita Matías-Florentino; Antoine Chaillon; Santiago Ávila-Ríos; Sanjay R Mehta; Héctor E Paz-Juárez; Manuel A Becerril-Rodríguez; Silvia J Del Arenal-Sánchez; Alicia Piñeirúa-Menéndez; Verónica Ruiz; Patricia Iracheta-Hernández; Israel Macías-González; Jehovani Tena-Sánchez; Florentino Badial-Hernández; Andrea González-Rodríguez; Gustavo Reyes-Terán Journal: J Antimicrob Chemother Date: 2020-03-01 Impact factor: 5.790
Authors: Yanink Caro-Vega; Fernando Alarid-Escudero; Eva A Enns; Sandra Sosa-Rubí; Carlos Chivardi; Alicia Piñeirúa-Menendez; Claudia García-Morales; Gustavo Reyes-Terán; Juan G Sierra-Madero; Santiago Ávila-Ríos Journal: Pathogens Date: 2021-12-01